https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/352 2026-04-04T07:39:02Z 2026-04-04T07:39:02Z Lee, Young Ho Song, Gwan Gyu https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/64112 2025-10-05T11:17:17Z 2024-12-01T00:00:00Z

Title: Circulating Vitamin D Levels in Patients With Systemic Sclerosis: a Meta-Analysis Authors: Lee, Young Ho; Song, Gwan Gyu Abstract: Objective This study aimed to evaluate the relationship between circulating vitamin D levels and systemic sclerosis and to establish an association between vitamin D deficiency and systemic sclerosis.Methods We performed a meta-analysis comparing the plasma/serum vitamin D levels and vitamin D deficiency between patients with systemic sclerosis and healthy controls and examined correlation coefficients between circulating vitamin D levels and the Rodnan score.Results Twenty-one studies involving 1,399 patients with systemic sclerosis and 1,311 controls were included. The systemic sclerosis group had significantly lower vitamin D levels than the control group. Stratification by ethnicity demonstrated significantly decreased vitamin D levels in patients with systemic sclerosis among European, Asian, Arab, Latin American, and mixed populations. Stratification by age, sex, and/or body mass index revealed significantly lower vitamin D levels in the systemic sclerosis group regardless of the adjustment. Subgroup analysis by sample size revealed significantly lower vitamin D levels in the systemic sclerosis group by small (n<100) and large sample numbers (n>100). Stratification by publication year revealed significantly lower vitamin D levels in the systemic sclerosis group in both recent and old publication years. However, no significant difference in vitamin D levels was observed between diffuse and limited types of systemic sclerosis. Vitamin D deficiency was significantly associated with systemic sclerosis. The meta-analysis of correlation coefficients revealed a tendency of inverse correlation between circulating vitamin D levels and the Rodnan score.Conclusions Patients with systemic sclerosis had lower circulating vitamin D levels and higher vitamin D deficiency and there was a tendency of inverse correlation between circulating vitamin D levels and the Rodnan score.

2024-12-01T00:00:00Z Lee, Young Ho Song, Gwan Gyu https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/64234 2024-11-11T09:01:01Z 2024-02-01T00:00:00Z

Title: Role of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as potential biomarkers in Behcet′s disease: a meta-analysis Authors: Lee, Young Ho; Song, Gwan Gyu Abstract: Aim: The mean platelet volume (MPV), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) have attracted interest as possible indicators of inflammation and disease activity in various diseases. This meta-analysis assessed the association between NLR, MPV, PLR, and Behcet ' s disease (BD) and their correlation with disease activity and thrombosis. Methods: A thorough search of the Medline, Embase, and Cochrane databases was performed to identify relevant studies. Studies comparing NLR, MPV, and PLR between patients with BD and healthy controls, as well as studies examining these measures in connection with disease activity and thrombosis in BD satisfied the inclusion criteria. The standardized mean difference ( SMD) and 95% confidence interval (CI) were used to calculate the effect sizes. Results: This meta-analysis included 24 articles. The findings revealed no discernible differences in MPV between the BD and control groups (p= 0.992). NLR was substantially higher in the BD group than in the control group (p < 0.001). PLR was higher in the BD group than in the control group (p= 0.030), indicating that BD is associated with a larger PLR. Patients with active and inactive BD did not vary significantly in terms of disease activity according to the MPV. Comparing MPV between patients with BD with and without thrombosis showed no discernible changes. However, individuals with active BD had a considerably higher NLR and PLR than those with inactive BD (p= 0.003 and p= 0.005, respectively). The statistical significance threshold for the association between NLR, PLR, and thrombosis in patients with BD was not met. Conclusion: NLR and PLR can be regarded as general markers of inflammation according to the results of this meta-analysis.

2024-02-01T00:00:00Z Lee, Young Ho Song, Gwan Gyu https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/62338 2024-11-11T09:30:08Z 2024-02-01T00:00:00Z

Title: Comparison of the efficacy and safety of tocilizumab, sarilumab, and olokizumab in patients with active rheumatoid arthritis: a network meta-analysis of randomized controlled trials Authors: Lee, Young Ho; Song, Gwan Gyu Abstract: Objective This study compared the relative efficacy and safety of olokizumab, tocilizumab, and sarilumab in rheumatoid arthritis (RA) patients who were intolerant or responding inadequately to methotrexate (MTX). Methods We performed a Bayesian network meta-analysis to combine direct and indirect evidence from randomized controlled trials (RCTs) to examine the efficacy and safety of olokizumab, tocilizumab, and sarilumab in RA patients who were intolerant or responding inadequately to MTX. Results Six RCTs comprising 4439 patients met the inclusion criteria. Tocilizumab, sarilumab, olokizumab, and adalimumab treatments achieved a significant American College of Rheumatology 20% (ACR20) response rate compared with placebo. However, tocilizumab was associated with the most favorable surface area using the cumulative ranking curve (SUCRA) for the ACR20 response rate. The ranking probability based on the SUCRA indicated that tocilizumab treatment had the highest probability of providing the best ACR20 response rate, followed by sarilumab, olokizumab every 2 weeks (Q2W), olokizumab Q4W, adalimumab 40 mg, and placebo. The ACR50 and 70 response rates showed a distribution pattern similar to that of the ACR20 response rate. However, olokizumab Q4W had a higher ranking probability than olokizumab Q2W. The SUCRA rating showed that the placebo was the best intervention with the least adverse events (AEs) and withdrawal due to AEs, followed by interleukin‑6 inhibitors. Conclusion Tocilizumab, sarilumab, and olokizumab are more effective than adalimumab and have similar efficacy and safety in RA patients with inadequate responses to MTX.

2024-02-01T00:00:00Z Lee, Young Ho Song, Gwan Gyu https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/63415 2024-11-11T09:01:00Z 2024-02-01T00:00:00Z

Title: Comparison of the efficacy and safety of olokizumab at different dosages in patients with active rheumatoid arthritis: a network meta-analysis of randomized controlled trials Authors: Lee, Young Ho; Song, Gwan Gyu Abstract: Objective This study aimed to assess the relative efficacy and safety of olokizumab at different dosages in patients with active rheumatoid arthritis (RA). Methods We performed a Bayesian network meta-analysis to combine direct and indirect evidence from randomized controlled trials (RCTs) to examine the efficacy and safety of olokizumab administered intravenously to RA patients at 64 mg/kg every 2 or 4 weeks (Q2 or Q4W). Results Five RCTs comprising 2609 patients met the inclusion criteria. Both olokizumab Q2 and Q4W treatments achieved a significant American College of Rheumatology 20% response (ACR20) compared with the placebo (odds ratio [OR] 3.21, 95% credible interval [CrI] 2.53–4.09; OR 3.05, 95% CrI 2.43–3.86). However, olokizumab Q2W was associated with the most favorable surface using the cumulative ranking curve (SUCRA) for the ACR20 response rate. The ranking probability based on the SUCRA indicated that olokizumab Q2W had the highest probability of being considered the best treatment option for achieving the ACR20 response rate, followed by olokizumab Q4W, adalimumab, and placebo. The ACR50 and 70 response rates showed a similar distribution pattern to the ACR20 response rate, except that olokizumab Q4W had a higher-ranking probability than olokizumab Q2W for ACR50. The SUCRA rating likelihood of adverse events (AEs) and withdrawal due to AEs showed that a placebo was likely to be the best intervention. Conclusion Both olokizumab Q2 and Q4W were efficacious and well-tolerated treatments for active RA.

2024-02-01T00:00:00Z